FIBROSTATIN S.L. is a biomedicine company founded in 2005 as a spin-off of the University of Valencia and the Príncipe Felipe Research Center (CIPF). Its activity is based on the scientific results generated by the research group of Dr. Juan Saus in relation to the discovery and study of GPBP (Goodpasture Antigen-Binding Protein), a human protein whose hyperactivity has been related to highly relevant pathologies associated with inflammatory processes: autoimmune diseases (glomerulonephritis due to immune complexes, rheumatoid arthritis), chemoresistance in cancer, fibrosis and, more recently, type 2 diabetes.
FibroStatin has been declared an Innovative SME by the Ministry of Economy and Competitiveness (MINECO). The objective of FIBROSTATIN is to license products or patents to large pharmaceutical or bio-technological companies.
The information contained in this business data sheep has been provided by the company and the University of Valencia Science Park Foundation (FPCUV) is not responsible for its content.
Its technological resources synthesize and characterise any type of organic product, either through conventional synthesis in solution, in solid phase, or in fluorous phase.
Parr Pressure reactor.
Biotage 2.5 microwave reactor.
Hitachi HPLC with diode-array detector.
Laboratory for the production of recombinant proteins. It has technological resources to express, purify, characterise and store recombinant proteins from bacterial cultures.
Bacteria Cultivation: culture stove, refrigerated centrifuge (up to 1L volume).
Protein purification: FPLC ÄKTApurifier, affinity columns.
Protein characterisation: SDS-PAGE system and Western blot of BIO-RAD, image analysis system for chemioluminescence ChemiDoc-It ™ of UVP, spectrophotometer, SpectraMax Gemini plate fluorimeter from Molecular Devices, Hitachi HPLC with diode-array reader and columns of reverse phase (C18) and gel filtration.
Storage: freeze dryer of vials and freezers of -20/-80 ºC.
Cell biology laboratory: Intended for the culture of hybridomas to produce monoclonal antibodies and cell lines to test GPBP inhibitors with pharmacological potential (“ex vivo” models).
Eukaryotic culture: Laminar flow cabin type I, New Brunswick-Eppendorf CO2 stoves (2), inverted microscope, Eppendorf centrifuge (volume up to 1L).
Production of monoclonal antibodies: FiberCell Systems bio-reactors (2 pumps DUET PUMP).
Storage of cell lines: -150 ° C freezer.
Analytical resources: in addition to the plate fluorimeter, the laboratory will (as of September 2011) have has a Becton-Dickinson flow cytometer, a Leica inverted fluorescence microscope and a quantitative PCR from Applied Biosystems.
Benefits of Technology
FibroStatin Diagnostics focusSes on the development of procedures for “in vitro” diagnostics, based on GPBP detection in biological fluids and tissues.
FibroStatin Therapeutics generates and develops new compounds (both Small Molecule Entities -SMEs-, Monoclonal Antibodies -mAbs-, and peptides) for therapeutics based on GPBP inhibition of kinase activity, or in the reduction of circulating levels.
Unique know-how and expertise in GPBP-based technology. The company´s founders are the researchers who first identified GPBP, and who discovered its physiological role and its involvement in various human diseases.
This GPBP-based technology includes a new target and metabolic pathway with multiple market applications (virtually unknown in other companies) using the same expertise and technologies already available within the company. This allows transition between therapeutic indications without having to reinvent the existing platform.
Its initial market niche is that of autoimmune diseases and cancer, but it is expected to find new related markets derived from those already discovered.
The medical indications to which the FibroStatin products are directed are of a chronic nature, and with a complex therapeutic approach; to a large extent they are focussed on mAbs usage.
FibroStatin develops and patents therapeutic and diagnostic applications related to the GPBP (Goodpasture Antigen-binding Protein) protein, a new target and therapeutic biomarker, focussing its activity on chemo-resistant metastatic cancers and organ fibrosis.
The company has a portfolio of 45 patents approved on technologies associated with GPBP, including: inhibitory molecules, specific monoclonal antibodies, plus a wide range of medical uses.
Sectors to which company is directed
M.D, PhD. Juan Saus - Founder and Scientific Director
Associate Professor of the University of Valencia. Post-Doctorate at the Robert Wood Johnson School of Medicine and at Kansas University Medical Centre.
PhD. Francisco Revert - Founder and Director of Molecular and Bio-Chemistry
Degree in Biological Sciences and a PhD. in Pharmacy at the University of Valencia. Post-Doctorate at the Prince Felipe Research Centre.
PhD. Fernando Revert - Founder and Cellular Biology Director
PhD in Pharmacy at the University of Valencia; Post-Doctorate at the Prince Felipe Research Centre.
B.S. Luis Castillo - Director General
Industrial Engineer and Advanced Studies Engineer at the Polytechnic University of Valencia.
PhD. J Wesley Fox III - President and FibroStatin Inc. CEO
More than 25 years of experience in the sector. Co-Founder of NephroGenex, BioStratum, EnzyMed and RiboGene. R+D + I positions in Abbott Laboratories and Baxter Healthcare.
J.D., RAC J. Wesley Fox IV - Director of Business Development and Regulatory Affairs
Regulatory affairs consultant certified by RAC, working with pharmaceutical companies in the development stage.
Francisco Ruizfibrostatin@fibrostatin.comPhone: (+34) 960 000 802